Jan 29, 2019   SOURCE: PR NewsWire

Array BioPharma to Report Financial Results for the Second Quarter of Fiscal 2019 on February 5, 2019

BOULDER, Colo., Jan. 29, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the second quarter of fiscal 2019 and hold a conference call to discuss those results on Tuesday, February 5, 2019. Ron Squarer, Chief Executive Officer, will lead the call.

                        Date:                  Tuesday, February 5, 2019


                        Time:                  9:00 a.m. Eastern Time


                        Toll-Free:    
            (844) 464-3927


                        Toll:         
            (765) 507-2598


                        Pass Code:                               9778144

Webcast, including Replay and Conference Call Slides:
https://edge.media-server.com/m6/p/5zkxjoof

About Array BioPharma
Array BioPharma Inc. is a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. Array markets BRAFTOVI(®) (encorafenib) capsules in combination with MEKTOVI(®) (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF(V600E) or BRAF(V600K) mutation in the United States and with partners in other major worldwide markets. Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array's pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Loxo Oncology), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi(®) (larotrectinib, partnered with Loxo Oncology) is approved in the United States and Ganovo(®) (danoprevir, partnered with Roche) is approved in China. For more information on Array, please visit www.arraybiopharma.com or follow @arraybiopharma on Twitter and LinkedIn.

CONTACT:
Array BioPharma
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate Communications
(303) 381-6600
ir@arraybiopharma.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-second-quarter-of-fiscal-2019-on-february-5-2019-300786082.html

SOURCE Array BioPharma